External validation of a laparoscopic-based score to evaluate resectability for patients with advanced ovarian cancer undergoing interval debulking surgery

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4469-4474

  Chereau, Elisabeth ^a   Lavoue, V ^b   Ballester, M ^a   Coutant, C ^a   Selle, F ^a   Cortez, A ^a   Darai E ^a   Leveque, J ^b   Rouzier, R ^a  

^a HÔPITAL TENON   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

Interval debulking surgery; Optimal logistic regression; Ovarian cancer; Staging laparoscopy

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; INTERVAL DEBULKING SURGERY; LAPAROSCOPY; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; OVARY CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CALIBRATION; FEMALE; HUMANS; LAPAROSCOPY; MEDICAL ONCOLOGY; MIDDLE AGED; OVARIAN NEOPLASMS; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84855177993     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S and Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10): 943-953, 2010.
2. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL and Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248-1259, 2002. (Pubitemid 34177431)
3. Tangjitgamol S, Manusirivithaya S, Laopaiboon M and Lumbiganon P: Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2009: CD006014.
4. Bristow RE and Chi DS: Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 103: 1070-1076, 2006. (Pubitemid 44821335)
5. Fagotti A, Ferrandina G, Fanfani F, Ercoli A, Lorusso D, Rossi M and Scambia G: A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol 13: 1156-1161, 2006. (Pubitemid 44337976)
6. Brun JL, Rouzier R, Uzan S and Darai E: External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score. Gynecol Oncol 110: 354-359, 2008.
7. Fagotti A, Fanfani F, Vizzielli G, Gallotta V, Ercoli A, Paglia A, Costantini B, Vigliotta M, Scambia G and Ferrandina G: Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery? Gynecol Oncol 116: 72-77, 2010.
8. Bristow RE, Eisenhauer EL, Santillan A and Chi DS: Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 104: 480-490, 2007. (Pubitemid 46135675)
9. Gadducci A, Zola P, Landoni F, Maggino T, Sartori E, Bergamino T and Cristofani R: Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol 58: 42-47, 1995.
10. Chi DS, Zivanovic O, Palayekar MJ, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Leitao MM, Brown CL and Barakat RR: A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol Oncol 112: 6-10, 2009.
11. Chi DS, Venkatraman ES, Masson V and Hoskins WJ: The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 77: 227-231, 2000. (Pubitemid 30317140)
12. Chereau E, Ballester M, Rouzier R, Coutant C and Darai E. Advanced ovarian cancer: criteria of resectability. Bull Cancer 96: 1189-1197, 2009.
13. Gemer O, Lurian M, Gdalevich M, Kapustian V, Piura E, Schneider D, Lavie O, Levy T, Fishman A, Dgani R, Levavi H and Beller U: A multicenter study of CA125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer. Eur J Surg Oncol 31: 1006-1010, 2005. (Pubitemid 41671115)
14. Bristow RE, Duska LR, Lambrou NC, Fishman EK, O'Neill MJ, Trimble EL and Montz FJ: A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 89: 1532-1540, 2000.
15. Byrom J, Widjaja E, Redman CW, Jones PW and Tebby S: Can pre-operative computed tomography predict resectability of ovarian carcinoma at primary laparotomy? BJOG 109: 369-375, 2002. (Pubitemid 37338012)
16. Dowdy SC, Mullany SA, Brandt KR, Huppert BJ and Cliby WA: The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer 101: 346-352, 2004. (Pubitemid 38890839)
17. Ferrandina G, Sallustio G, Fagotti A, Vizzielli G, Paglia A, Cucci E, Margariti A, Aquilani L, Garganese G and Scambia G: Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial. Br J Cancer 101(7): 1066-1073, 2009.
18. Gasowska-Bodnar A, Bodnar L, Wcislo GB, Jerzak MM, Szczylik C and Baranowski W: CA125 regression after two cycles of neoadjuvant chemotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction. Ginekol Pol 79: 108-114, 2008.
19. Saygili U, Guclu S, Uslu T, Erten O and Dogan E: The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma. Int J Gynecol Cancer 12: 438-442, 2002.
20. Verleye L, Ottevanger PB and Vergote I: Surgical program building in advanced ovarian cancer: European perspective. Gynecol Oncol 114: S10-14, 2009.
21. Giede KC, Kieser K, Dodge J and Rosen B: Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol 99: 447-461, 2005. (Pubitemid 41502860)
22. Vernooij F, Heintz P, Witteveen E and van der Graaf Y: The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol Oncol 105: 801-812, 2007. (Pubitemid 46734206)
23. Munstedt K, von Georgi R, Misselwitz B, Zygmunt M, Stillger R and Kunzel W: Centralizing surgery for gynecologic oncology - a strategy assuring better quality treatment? Gynecol Oncol 89: 4-8, 2003. (Pubitemid 36403641)
24. Chi DS, Venkatraman ES, Masson V and Hoskins WJ: The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 77: 227-231, 2000. (Pubitemid 30317140)
25. Chi DS, Zivanovic O, Palayekar MJ, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Leitao MM, Brown CL and Barakat RR: A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol Oncol 112: 6-10, 2009.